Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of CVAT for Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT02761291Phase 1Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- May 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine, valproic acid and valganciclovir in nasopharyngeal carcinoma (NPC), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Dose Limiting Toxicity. Status: unknown.
02
Drugs
gemcitabinevalproic acidvalganciclovir
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02761291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761291.